Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets Indicate Bullish Outlook for Axsome Therapeutics

Elaine Mendonca by Elaine Mendonca
January 16, 2024
in Breaking News
0
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

As of January 16, 2024, the outlook for Axsome Therapeutics (NASDAQ:AXSM) appears to be largely positive based on recent analyst ratings and price targets. Over the past three months, the average price target for AXSM has been $119.29, with a high estimate of $180.00 and a low estimate of $108.00. This average target of $135.67 represents a substantial increase of 50.74% from the previous average price target of $90.00.

In the current month, AXSM has received 25 Buy Ratings, 1 Hold Rating, and 0 Sell Ratings from analysts. Notably, key analysts have taken actions such as raising price targets and maintaining buy ratings, which reflects their confidence in the company’s performance.

Here is a summary of the recent analyst ratings and price targets:

– David Amsellem from Piper Sandler has raised the rating to Overweight with a current price target of $113.00, up from the prior target of $90.00.
– Raghuram Selvaraju from HC Wainwright & Co. has maintained a Buy rating with a price target of $180.00.
– Charles Duncan from Cantor Fitzgerald has maintained an Overweight rating with a price target of $108.00.
– David Hoang from Citigroup has announced a Buy rating with a price target of $125.00.

The majority of analysts have given buy or overweight ratings, and their price targets are significantly higher than the current price. This indicates a positive sentiment towards the future performance of Axsome Therapeutics.

In conclusion, the analyst landscape for Axsome Therapeutics suggests a bullish outlook. The majority of analysts maintain buy ratings and have significantly increased their price targets, demonstrating confidence in the company’s future prospects.

AXSM Stock: Strong Performance and Positive Momentum in After-Hours Trading – January 16, 2024

On January 16, 2024, AXSM stock displayed a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. The price of AXSM shares experienced a slight decrease of $0.26 since the market closed, representing a drop of 0.31%. However, in after-hours trading, AXSM stock showed a positive momentum by rising $0.28. Investors may find AXSM stock appealing due to its strong performance relative to its 52-week range and the fact that it is trading above its 200-day simple moving average. It is important to note that stock prices can be influenced by various factors, including market conditions, company news, and economic trends. Therefore, it is crucial for investors to conduct thorough research and analysis before making any investment decisions.

AXSM Stock Performance: Mixed Results on January 16, 2024 – Importance of Monitoring Financial Reports and Market Factors

On January 16, 2024, AXSM stock experienced a mixed performance, with some positive and negative indicators. The net income for the company was reported to be -$187.13 million in the previous year, representing a 43.5% decrease compared to the previous year. However, there has been a slight improvement in the net income since the last quarter, with a reported figure of -$62.20 million, indicating a 7.4% increase. Similarly, the EPS for the previous year stood at -$4.60, showing a decrease of 32.79% compared to the previous year. However, there has been a positive change in EPS since the last quarter, with a reported figure of -$1.32, indicating a 14.17% increase. While the decrease in net income and EPS over the past year may raise concerns for investors, the recent improvements in these figures since the last quarter could be seen as a positive sign. However, it is important to note that without the total revenue data, it is challenging to gauge the overall financial performance of AXSM accurately. Investors and analysts should closely monitor AXSM’s financial reports, including the total revenue figures, to gain a more accurate understanding of the company’s financial health. It is also advisable to consider other factors such as market trends, industry performance, and any significant developments or announcements from AXSM that may impact its stock performance. In conclusion, AXSM’s stock performance on January 16, 2024, showcased a mixed bag of results. Investors should exercise caution and closely monitor AXSM’s financial reports and other market factors to make informed investment decisions.

Tags: AXSM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
SO stock news

Goldman Sachs CEO Optimistic for Positive Shift in Credit Card Partnerships

Technology Robotics Markets and money

Analyst Shows Confidence in Adtran with Buy Rating and Solid Price Target

Telecommunications Industry stock Trading

EchoStar Receives Coverage Initiation Following Successful Merger A Dominant Global Connectivity Leader Emerges

Recommended

Co-Diagnostics Stock

Co-Diagnostics Shares Plummet Following Dilutive Financing Move

5 months ago
Biotechnology Stock Market Today (1)

The Rise of OpenSource AI AbacusAIs Smaug72B Surpasses GPT35

2 years ago
Western Digital Stock

Western Digital Shares Maintain Extraordinary Rally

4 months ago
Precision BioSciences Inc Stock

Precision BioSciences Stock Surges on Gene-Editing Breakthroughs

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Copper’s Critical Role Powers Freeport-McMoRan’s Strategic Expansion

Western Digital’s Strategic Pivot Secures Dominance in Data Storage

Intuit Doubles Down on Share Buybacks Amid Market Pressure

Strategic Alliance Strengthens US Critical Minerals Independence

Zscaler’s Upward Revision: Security Demand in the AI Era Fuels Optimism

Coherent Stock Accelerates Toward New Highs on Key Breakthroughs

Trending

Atlassian Stock
AI & Quantum Computing

Atlassian Shares Hit Fresh Annual Low Amid Sector-Wide Concerns

by Jackson Burston
March 25, 2026
0

Atlassian stock touched a new 52-week low in today's trading session, declining by approximately eight percent. This...

Johnson & Johnson Stock

Institutional Investors Increase Stakes in Healthcare Giant Johnson & Johnson

March 25, 2026
Qualcomm Stock

Qualcomm Launches Major Capital Return Initiative Amid Strategic Shift

March 25, 2026
Freeport-McMoRan Stock

Copper’s Critical Role Powers Freeport-McMoRan’s Strategic Expansion

March 25, 2026
Western Digital Stock

Western Digital’s Strategic Pivot Secures Dominance in Data Storage

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Atlassian Shares Hit Fresh Annual Low Amid Sector-Wide Concerns
  • Institutional Investors Increase Stakes in Healthcare Giant Johnson & Johnson
  • Qualcomm Launches Major Capital Return Initiative Amid Strategic Shift

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com